Cardinal lifts FY profit outlook again on strong sales of specialty drugs

Posted on:
Key Points

Nov 3 (Reuters) - Drug distributor Cardinal Health (CAH.N) on Friday raised its full-year earnings forecast for the second time in nearly three months, betting on strong demand for specialty medicines...

Drug distributors have been benefiting from strong sales of highly priced specialty medicines that treat diseases including cancer and rheumatoid arthritis, while prices of generic medicines have fallen due to intense competition...

The company expects profit for its pharmaceutical segment, through which it distributes branded drugs, generic drugs and specialty medicines, to rise 7% to 9% during the financial year 2024, up from its previous forecast of 4% to 6% growth...

You might be interested in

India's Cipla Q3 profit tops estimates on North America sales boost

23, Jan, 24

BENGALURU/HYDERABAD (Reuters) -Indian generic drugmaker Cipla on Monday reported its third-quarter profit above analysts expectations, boosted by strong performances in North American and domestic

India's ITC beats Q1 profit view on strong FMCG demand, drop in expenses

14, Aug, 23

India's ITC Ltd (ITC.NS) reported a bigger-than-expected rise in first-quarter profit on Monday, buoyed by strong demand in the FMCG segment and as expenses fell.

India's Coforge Q3 profit rises on deal wins, maintains FY revenue forecast

22, Jan, 24

BENGALURU (Reuters) - Indian IT services company Coforge reported a 4.3% increase in third-quarter profit, aided by deal wins in a challenging macroeconomic environment, and reiterated its revenue

Warner Bros earns $50 million in Q1 from online TV; total subscribers plunges to 97.6 million

06, May, 23

The company reported a surprise profit in streaming TV as its legacy cable networks continued to lose advertising and viewers.

24 mega-seller drugs set to lose patents in US, big opportunity for Indian drugmakers — govt report

30, Apr, 24

Patent expiry would mean that drugmakers will be able to launch generic versions of the blockbuster drugs, which are typically priced up to 90 percent lower than their innovator drug.

India's Prestige Estates Projects posts higher Q2 profit on strong housing demand

07, Nov, 23

India's Prestige Estates Projects (PREG.NS) reported a more than six-fold jump in second-quarter profit on Tuesday, aided by a buoyant housing demand.

Johnson & Johnson forecasts as much as 6% sales growth in 2024

05, Dec, 23

Johnson & Johnson (JNJ.N) on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara.

HP forecasts downbeat first-quarter profit amid slow PC market recovery

22, Nov, 23

HP Inc (HPQ.N) on Tuesday forecast first-quarter profit below Wall Street estimates but maintained its annual earnings outlook, a sign that demand in the personal computers market is still recovering.

PepsiCo lifts profit forecast again as price hikes fail to dent demand

10, Oct, 23

International Business News: PepsiCo Inc on Tuesday raised its annual profit forecast for a third time this year, as the company banks on the multiple price increases it had under.

16 smallcap stocks with over 100% growth in profit & sales. Watchlist these tiny tornadoes!

28, Feb, 24

India Inc's December quarter earnings showed weakening profit momentum at an overall level but we filtered out a list of 16 smallcap companies which reported over 100% growth in sales and profit on a YoY basis. Waaree Renewable Technologies, Advait Infratech, Cressanda Railway Solutions, and Swelect Energy Systems were among the top performers. 14 out of 16 of these stocks have already given multibagger returns in last one year.